Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

Oppenheimer has recently initiated Capricor Therapeutics Inc (CAPR) stock to Outperform rating, as announced on May 17, 2024, according to Finviz. Earlier, on January 5, 2024, Cantor Fitzgerald had ...

Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), Tuesday announced a deal with Japan-based Nippon Shinyaku Co., Ltd., to commercialize and distribute deramiocel in Europe, which is used for the ...

US biotech Capricor Therapeutics has entered into a binding term sheet with Japanese drugmaker Nippon Shinyaku for the ...

Plus, news about Vigil Neuroscience, AC Immune and Athira Pharma: Capricor Therapeutics, Nippon Shinyaku expand commercial pact into Europe: The new deal builds off an existing partnership for a ...

Capricor will receive an upfront payment of $20 million subject to execution of the definitive agreement, and there are potential additional development and sales-based milestone payments to Capricor ...

Capricor Therapeutics (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku, a Japanese pharmaceutical company, for the commercialization and distribution in Europe of Capricor’s lead ...

Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese ...